Kura Oncology (KURA) Earnings Analysis

Kura Oncology (KURA) next reports earnings on 2026-08-06, consensus EPS -0.89 USD. Last quarter (2026-03-05) it missed with EPS -0.92 USD vs -0.72 USD est (-27.8%). It has beaten estimates in 2/5 recent quarters (40%). Trailing P/E -3.15.

Last updated 2026-07-23 · Source: FMP fundamentals + earnings calendar (company filings); consensus from sell-side analyst grades

When does KURA next report earnings?

Next earnings date2026-08-06
Consensus EPS estimate-0.89 USD
Revenue estimate0.02B

KURA earnings history — beats and misses

Quarter (report date)EPS actualEPS est.SurpriseResult
2026-03-05-0.92 USD-0.72 USD-27.8%Miss
2025-08-07-0.75 USD0.15 USD-600%Miss
2025-05-01-0.66 USD-0.51 USD-29.4%Miss
2025-02-26-0.22 USD-0.65 USD+66.2%Beat
2024-11-07-0.63 USD-0.64 USD+1.6%Beat

Beat rate: 2/5 (40%) over reported quarters with consensus data.

KURA valuation and analyst view

Trailing P/E-3.15
Trailing EPS-3.32434 USD
Price / book8.66
Dividend yield0.00%
Market cap0.94B
Analyst consensusBuy (15 buy / 2 hold / 0 sell)
Avg price target24 USD

Related research pages

Frequently asked questions

When is Kura Oncology (KURA)'s next earnings date?

Kura Oncology is next scheduled to report on 2026-08-06, with a consensus EPS estimate of -0.89 USD and revenue estimate of 0.02B.

Did KURA beat earnings last quarter?

In its 2026-03-05 report, KURA posted EPS of -0.92 USD versus a -0.72 USD estimate — a miss of 27.8%.

What is KURA's earnings track record?

Over the last 5 reported quarters with consensus data, KURA beat estimates 2 times (40%).

What is KURA's current P/E ratio and EPS?

KURA trades at a trailing P/E of -3.15 on trailing EPS of -3.3243426249858934 USD.

What do analysts rate KURA?

Analyst consensus is "Buy" across 17 ratings (0 strong buy, 15 buy, 2 hold, 0 sell, 0 strong sell). Average 12-month price target: 24 USD.